Asia Pacific Active Pharmaceutical Ingredients (API) Market 2022-2032 by Molecule (Small, Large), Synthesis (Synthetic, Biotech, HPAPI), Manufacturing Process (Captive, Merchant), Therapeutic Application, Drug Type, and Country: Trend Forecast and Growth Opportunity

Asia Pacific active pharmaceutical ingredients (API) market will grow by 8.1% annually with a total addressable market cap of $ 1,098.6 billion over 2023-2032, driven by rising adoption of biologics in disease management, increasing regulatory approvals, patent expiration of major drugs, growing trend of outsourcing and increase in geriatric population.
Highlighted with 88 tables and 75 figures, this 196-page report "Asia Pacific Active Pharmaceutical Ingredients (API) Market 2022-2032 by Molecule (Small, Large), Synthesis (Synthetic, Biotech, HPAPI), Manufacturing Process (Captive, Merchant), Therapeutic Application, Drug Type, and Country: Trend Forecast and Growth Opportunity" is based on a comprehensive research of the entire Asia Pacific active pharmaceutical ingredients (API) market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2020-2022 and provides forecast from 2023 till 2032 with 2022 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter's Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Asia Pacific active pharmaceutical ingredients (API) market in every aspect of the classification from perspectives of Molecule, Synthesis, Manufacturing Process, Therapeutic Application, Drug Type, and Country.

Based on Molecule, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Small Molecule APIs
• Large Molecule APIs

Based on Synthesis, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Synthetic API
o Branded Synthetic API
o Generic Synthetic API
• Biotech API
o by type
 Monoclonal Antibodies
 Recombinant Proteins
 Vaccines
 Other Biotech APIs
o by Category
 Innovative Biologic API
 Generic Biosimilar API
o by Expression
 Mammalian Expression
 Microbial Expression
 Yeast Expression
 Insect Expression
 Other Expression Technologies
• HPAPI
o Branded HPAPI
o Generic HPAPI

Based on Manufacturing Process, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Captive Manufacturing
o Branded Captive API
o Generic Captive API
• Merchant Manufacturing
o by Drug Type
 Branded Merchant API
 Generic Merchant API
o by Drug Synthesis
 Merchant Synthetic API
 Merchant Biotech API

By Therapeutic Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Infectious Diseases
• Oncology
• Ophthalmology
• Cardiovascular Disorders
• Central Nervous System
• Pulmonary Disorders
• Orthopedics
• Other Applications

By Drug Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Branded Prescription Drugs
• Generic Prescription Drugs
• OTC Drugs

Geographically, the following national/local markets are fully investigated:
• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2022-2032. The breakdown of national markets by Synthesis, Manufacturing Process, and Therapeutic Application over the forecast years are also included.

The report also covers the current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
AbbVie Inc.
Astrazeneca
Aurobindo Pharma Ltd.
BASF
Bayer AG
Boehringer Ingelheim
Catalent Inc.
Dr. Reddy's Laboratories
F. Hoffmann-La Roche
GlaxoSmithKline plc
Lonza Group
Lupin Limited
Merck & Co., Inc.
Mylan NV
Novartis International AG
Pfizer Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Thermo Fisher Scientific
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)